

**SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934  
(Amendment No. \_\_)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to § 240.14a-12

**FINCH THERAPEUTICS GROUP, INC.**  
(Name of Registrant as Specified In Its Charter)

\_\_\_\_\_  
(Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- No fee required.
  - Fee paid previously with preliminary materials
  - Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
-

**Finch Therapeutics Group, Inc.  
Important Notice Regarding the Availability  
of Proxy Materials**

**Stockholders Meeting to be held on  
June 8, 2023**

**For Stockholders of record as of April 10, 2023**

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy materials, including the proxy statement and the annual report to stockholders, and to obtain directions to attend the meeting, go to: [www.proxydocs.com/FNCH](http://www.proxydocs.com/FNCH)

To vote your shares while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.



**For a convenient way to view proxy materials and VOTE go to  
[www.proxydocs.com/FNCH](http://www.proxydocs.com/FNCH)**

**Have the 12 digit control number located in the shaded box above available  
when you access the website and follow the instructions.**

*If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 29, 2023.*

*To order paper materials, use one of the following methods.*

  
**INTERNET**  
[www.investorelections.com/FNCH](http://www.investorelections.com/FNCH)

  
**TELEPHONE**  
**(866) 648-8133**

  
**\* E-MAIL**  
[paper@investorelections.com](mailto:paper@investorelections.com)

When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.

\* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

**Finch Therapeutics Group, Inc.**

**Meeting Type:** Annual Meeting of Stockholders  
**Date:** Thursday, June 8, 2023  
**Time:** 10:30 AM, Eastern Time  
**Place:** Annual Meeting to be held live via the Internet - please visit [www.proxydocs.com/FNCH](http://www.proxydocs.com/FNCH) for more details

**You must register to attend the meeting online by 5:00 PM ET on June 6, 2023 at [www.proxydocs.com/FNCH](http://www.proxydocs.com/FNCH)**

**SEE REVERSE FOR FULL AGENDA**

# Finch Therapeutics Group, Inc.

## Annual Meeting of Stockholders

**THE BOARD OF DIRECTORS RECOMMENDS A VOTE:**

**FOR ALL NOMINEES FOR DIRECTOR IN PROPOSAL 1, FOR PROPOSAL 2 AND FOR PROPOSAL 3**

**PROPOSAL**

1. To elect two nominees to the positions of Class II director, each to hold office until the Annual Meeting of Stockholders in 2026.
    - 1.01 Susan Graf
    - 1.02 Chris Shumway
  2. To ratify the selection by the audit committee of the board of directors of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
  3. To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's issued and outstanding common stock at a ratio of 1-for-30.
  4. To conduct any other business properly brought before the meeting.
-

